Skip to content

Veracyte VCYT Investing Cash Flow

Investing Cash Flow at other companies

Guardant Health logo
Guardant HealthGH
$699.42M+131%
Natera, Inc. logo
Natera, Inc.NTRA
-$32.14M-91.1%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
-$93.2M-3,314%
Revvity logo
RevvityRVTY
-$78.27M-1,127%
Labcorp Holdings logo
Labcorp HoldingsLH
-$322.1M+4.1%
Quest Diagnostics logo
Quest DiagnosticsDGX
-$152M-32.2%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's investing cash flow?
Veracyte (VCYT) reported investing cash flow of -$127.96M in Q1 2026.
How has Veracyte's investing cash flow changed year-over-year?
Veracyte's investing cash flow decreased by 146.9% year-over-year, from -$51.82M to -$127.96M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.